Quanterix

QTRXPre-clinical

Quanterix is a public company focused on advancing precision health through its groundbreaking Simoa technology, which allows for the detection of biomarkers at the single-molecule level. This capability is critical for early disease detection, monitoring, and therapeutic development, particularly in complex areas like neurodegenerative diseases. The company operates both as a technology platform provider, selling instruments and consumables, and as a diagnostic services partner, positioning itself at the forefront of the digital biomarker revolution.

Market Cap

$200.9M

Employees

300-500

Focus

Biotech

QTRX · Stock Price

USD 4.2822.96 (-84.29%)

Historical price data

AI Company Overview

Technology Platform

The Simoa (Single Molecule Array) platform is a digital immunoassay technology that enables the detection and quantification of protein biomarkers at sub-femtomolar concentrations—up to 1,000 times more sensitive than conventional assays—by isolating and detecting single molecules.

Funding History

Total raised: $216M

IPO$96MUndisclosedJul 15, 2017

Series C$60MBain Capital VenturesJun 15, 2014

Series B$40MBain Capital VenturesJun 15, 2011

Series A$20MARCH Venture PartnersJun 15, 2008

Opportunities

Major growth opportunities include the expansion of its biomarker menu into new disease areas, the transition of its research assays into FDA-cleared in vitro diagnostics for clinical use, and deepening partnerships with large pharma for drug development support.

The global push for early disease detection and liquid biopsy applications in oncology presents a massive addressable market.

Risk Factors

Key risks include slower-than-expected adoption of its technology in clinical diagnostics, intense competition from larger, well-funded diagnostic companies, reliance on the neurology research market, and the financial challenge of achieving profitability while funding significant R&D and regulatory efforts.

Competitive Landscape

Quanterix competes with large diagnostic firms like Roche, Abbott, and Thermo Fisher, which offer traditional immunoassays, and with specialized players like Olink in high-sensitivity proteomics. Its primary differentiation is its commercially proven single-molecule detection technology, which offers superior sensitivity, giving it a first-mover advantage in key research areas like neurology.